Abstract:Background The association between inflammation and major depressive disorder (MDD) remains poorly understood, given the heterogeneity of patients with MDD. Aims We investigated inflammatory markers, such as interleukin (IL)-6, high-sensitivity C reactive protein (hsCRP) and tumour necrosis factor-α (TNF-α) in melancholic, atypical and anxious depression and explored whether baseline inflammatory protein levels could indicate prognosis. Methods The sample consisted of participants (aged 18–55 years) from a previously reported multicentre randomised controlled trial with a parallel-group design registered with ClinicalTrials.gov, including melancholic (n=44), atypical (n=37) and anxious (n=44) patients with depression and healthy controls (HCs) (n=33). Subtypes of MDD were classified according to the 30-item Inventory of Depressive Symptomatology, Self-Rated Version and the 17-item Hamilton Depression Rating Scale. Blood levels of TNF-α, IL-6 and hsCRP were assessed using antibody array analysis. Results Patients with MDD, classified according to melancholic, atypical and anxious depression subtypes, and HCs did not differ significantly in baseline TNF-α, IL-6 and hsCRP levels after adjustment. In patients with anxious depression, hsCRP levels increased significantly if they experienced no pain (adjusted (adj.) p=0.010) or mild to moderate pain (adj. p=0.038) compared with those with severe pain. However, the patients with anxious depression and severe pain showed a lower trend in hsCRP levels than patients with atypical depression who experienced severe pain (p=0.022; adj. p=0.155). Baseline TNF-α (adj. p=0.038) and IL-6 (adj. p=0.006) levels in patients in remission were significantly lower than those in patients with no remission among the participants with the atypical depression subtype at the eighth-week follow-up. Conclusions This study provides evidence of differences in inflammatory proteins in patients with varied symptoms among melancholic, atypical and anxious depression subtypes. Further studies on the immunoinflammatory mechanism underlying different subtypes of depression are expected for improved individualised therapy. Trial registration number NCT03219008 .

The Plasma IL-18, MIP-1α, MCP-1, SDF-1 and Rantes in Patients with Majior Depression

Fluoxetine Treatment for Major Depression Decreases the Plasma Levels of Cytokines

Linking peripheral IL-6, IL-1 and hypocretin-1 with cognitive impairment from major depression

Increased Plasma Levels of IL-6 Are Associated with Striatal Structural Atrophy in Major Depressive Disorder Patients with Anhedonia

Increased Plasma Concentrations of Interleukin-6, Soluble Interleukin-6, Soluble Interleukin-2 and Transferrin Receptor in Major Depression.

The relationship between plasma cytokine levels and antidepressant response in patients with first-episode major depressive disorder

The Changes In, and Relationship Between, Plasma Nitric Oxide and Corticotropin‐releasing Hormone in Patients with Major Depressive Disorder

Plasma Levels of Interleukin-6, Interleukin-10, and Interleukin-1 Receptor Antagonist in Depression: Comparison Between the Acute State and after Remission

Tumor Necrosis Factor- Variations in Patients With Major Depressive Disorder Before and After Antidepressant Treatment

Changes in the Serum Levels of Inflammatory Cytokines in Antidepressant Drug-Naïve Patients with Major Depression

Tumor Necrosis Factor-α Variations in Patients With Major Depressive Disorder Before and After Antidepressant Treatment

Increased Serum IL-6 and IL-1 Receptor Antagonist Concentrations in Major Depression and Treatment Resistant Depression.

A Preliminary Investigation on Plasma Cell Adhesion Molecules Levels by Protein Microarray Technology in Major Depressive Disorder

Ndt_a_202329 1695..1700

Peripheral Cytokine Levels and Response to Antidepressant Treatment in Depression: a Systematic Review and Meta-Analysis

Relaitonship of mean platelet volume to MDD: a retrospecitve study

Association between inflammatory cytokines and symptoms of major depressive disorder in adults

The Study of Level Changes of Serum Cytokine, C-reactive Protein and Zinc in Patients with Depression at Pre- and Post-Treatment of Paroxetine

TNF-α, IL-6 and hsCRP in patients with melancholic, atypical and anxious depression: an antibody array analysis related to somatic symptoms

Prospective study on Maresin-1 and cytokine levels in medication-naïve adolescents with first-episode major depressive disorder

Cytokines and serotonin transporter in patients with major depression